ArticleDermatologic therapy2022
Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.
Article in Dermatologic therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Bloodletting cupping combined with conventional measures therapy for psoriasis: A systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2023Pooled it
- The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2023Pooled it
- Liver fibrosis prevalence and risk factors in patients with psoriasis: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- The Impact of Biologic Therapy on Quality of Life and Mental Health in Patients with Psoriasis.Journal of clinical medicine · 2026Review
- IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?Journal of inflammation research · 2026Review
- A 76-week real-world multidimensional analysis of guselkumab in moderate to severe plaque psoriasis: a retrospective cohort study based on Chinese clinical practice standards.Frontiers in immunology · 2026Article
- Long-Term Outcomes of Guselkumab and Risankizumab for the Management of Moderate-to-Severe Psoriasis in the Elderly: Results from a Real-World Retrospective Study.Journal of clinical medicine · 2025Article
- New Interleukin-23 Antagonists' Use in Crohn's Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis.Dermatology and therapy · 2024Article
- Real Life Comparative Effectiveness of IL-23 Inhibitors in the Treatment of Moderate to Severe Psoriasis: A Multicenter Experience.Dermatology practical & conceptual · 2024Article
- Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data.Frontiers in immunology · 2024Article
- Prevalence of metabolic syndrome and chronic inflammation in psoriasis before and after biologic therapy: a prospective study.Medicine and pharmacy reports · 2023Article
- Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database.Pharmaceutics · 2023Article
- Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation.Clinical drug investigation · 2023Article
- The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review.Biomedicines · 2023Review
- Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics.Pediatric health, medicine and therapeutics · 2023Review
- Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study.Clinical, cosmetic and investigational dermatology · 2023Article
- Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study.Clinical, cosmetic and investigational dermatology · 2023Article
- JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series.Frontiers in medicine · 2023Article
- Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting.Dermatologic therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-23-inhibitors, such as guselkumab and risankizumab, represent the newest class of biologics approved for psoriasis. Phase III trials have shown their efficacy and safety. However, real life data are still scant. to indirectly compare the effectiveness, safety and tolerability of guselkumab and risankizumab in real world practice. An Italian single-center retrospective cohort study enrolling moderate-to-severe psoriasis patients from September 1, 2018 and December 31, 2020 was performed to indirectly compare guselkumab and risankizumab efficacy and safety. Sixty eight patients were included (36 received guselkumab and 32 risankizumab). The groups were comparable for all analyzed characteristics, except for mean psoriasis duration (p < 0.01) which was higher for guselkumab. In guselkumab group, mean PASI reduced from 16.1 ± 6.4 (baseline) 2.1 ± 0.9 (week-28) (p < 0.001) up to 0.9 ± 0.8 (week-44) (p < 0.001). In risankizumab group mean PASI decreased from 13.5 ± 4.9 (baseline) 1.9 ± 0.8 (p < 0.001), (week-28) (p < 0.001) up to 0.9 ± 0.4 (week-40) (p < 0.001). No significant difference in mean PASI and BSA were observed between the treatments. No cases of serious AEs, injection site reaction, candida, malignancy, cardiovascular events were reported in both groups. Guselkumab and risankizumab showed favorable efficacy and safety profile, being comparable in terms of PASI90 and PASI100 responses as well as in AEs frequency and discontinuation rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.